Bailey & Ors v Glaxosmithkline (UK) Ltd

Bailey & Ors v Glaxosmithkline (UK) Ltd

The Claimants are not entitled, on their pleadings, to submit that Seroxat has no relative benefits compared to other SSRIs or to invite the court to assume a 'level playing field' of risks and benefits. The case is confined to the pleaded allegation that Seroxat is 'worst in class' for discontinuation symptoms, and any expansion to a holistic risk/benefit analysis is impermissible at this stage.

Parties
Claimants: Sandra Bailey & Others; Defendant: GlaxoSmithKline UK Limited
Jurisdiction
England and Wales
Judgment Date
09 May 2019
Procedural Posture
Product Liability Group Litigation / Interlocutory Ruling During Trial
Outcome
Claimants' submission on a 'level playing field' of risks and benefits rejected; case confined to pleaded issues.
Legal Topics
Defective Products, Pleadings, Comparative Risk/benefit Analysis, Group Litigation Orders, Case Management
Product Liability Consumer Protection Civil Procedure Defective Products Pleadings Comparative Risk/benefit Analysis Group Litigation Orders Case Management

Case Brief

Summary, issues, holding and outcome

More case intelligence is available

Unlock the full research layer for this judgment.

Full judgment text Downloadable case file Legal principles 2 Authorities cited 4 Party arguments 2
Sign in to unlock

Parties

Sandra Bailey & Others

Claimants

GlaxoSmithKline UK Limited

Defendant

Procedural Posture

Product Liability Group Litigation / Interlocutory Ruling During Trial

Legal Issues

  1. 1 Whether the Claimants can argue that Seroxat has no relative benefits compared to other SSRIs based on the pleadings
  2. 2 Whether the court should assume a 'level playing field' of risks and benefits among SSRIs except for the alleged defect in Seroxat
  3. 3 Whether the Claimants' case on defect includes a holistic risk/benefit analysis or is limited to 'worst in class' for discontinuation symptoms

Ratio Decidendi

The Claimants are not entitled, on their pleadings, to submit that Seroxat has no relative benefits compared to other SSRIs or to invite the court to assume a 'level playing field' of risks and benefits. The case is confined to the pleaded allegation that Seroxat is 'worst in class' for discontinuation symptoms, and any expansion to a holistic risk/benefit analysis is impermissible at this stage.

Court Disposition

Claimants' submission on a 'level playing field' of risks and benefits rejected; case confined to pleaded issues.

Orders

  • Claimants not permitted to argue at trial that Seroxat has no relative benefits compared to other SSRIs.
  • Trial to proceed only on the basis of the current pleadings as previously analysed by Foskett J and the court.